Microneedles for Drug Delivery via the Gastrointestinal Tract
Author(s)Schroeder, Avi; Maa, Ruby C.; Lauwers, Gregory Y.; Polat, Baris E.; Blankschtein, Daniel; Langer, Robert; Traverso, Gio; Schoellhammer, Carl Magnus; Anderson, Daniel Griffith; ... Show more Show less
MetadataShow full item record
Both patients and physicians prefer the oral route of drug delivery. The gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics because of its protease and bacteria-rich environment as well as general pH variability from pH 1 to 7. These extreme environments make oral delivery particularly challenging for the biologic class of therapeutics. Here, we demonstrate proof-of-concept experiments in swine that microneedle-based delivery has the capacity for improved bioavailability of a biologically active macromolecule. Moreover, we show that microneedle-containing devices can be passed and excreted from the GI tract safely. These findings strongly support the success of implementation of microneedle technology for use in the GI tract.
DepartmentInstitute for Medical Engineering and Science; David H. Koch Institute for Integrative Cancer Research at MIT; Harvard University--MIT Division of Health Sciences and Technology; Massachusetts Institute of Technology. Department of Chemical Engineering
Journal of Pharmaceutical Sciences
Traverso, Giovanni, Carl M. Schoellhammer, Avi Schroeder, Ruby Maa, Gregory Y. Lauwers, Baris E. Polat, Daniel G. Anderson, Daniel Blankschtein, and Robert Langer. “Microneedles for Drug Delivery via the Gastrointestinal Tract.” J. Pharm. Sci. (September 2014).
Author's final manuscript